Our aim is to keep investors and interested parties informed of Uscom news events and announcements
The interview with Alan Kohler was focused on the sustainability of our transformational first profit and triple-digit growth, and the foreseeable upside for Uscom China during the Chinese post-viral economic rebound, and the worldwide COVID-19 effect.
NWR Virtual Small Cap Investor Conference on the 26th March 2020 allowed us to present the pre-4C results up to 23-3-20. For the shortened period we reported a $0.33M Profit, our first quarterly profit from operations alone, record cash receipts of $2.14M, cash flow positivity $0.99M, with cash on hand of $2.47M, and we remained debt free. These results were attributable to the first quarter of operations of Uscom China. The presentation was received well.
SYDNEY, Australia, Monday 24th February 2020: Uscom Limited (ASX code: UCM) (the Company or Uscom) today announced the inclusion of USCOM 1A technology in the Society of Critical Care Medicine guidelines for treatment of severe sepsis in children. This represents the culmination of 15 years of research and development and directed clinical practice in the field of sepsis and paediatric sepsis by Uscom scientists and engineers, and its key opinion leaders.
SYDNEY, Australia, Monday 10th February 2020: Uscom Limited (ASX code: UCM) (the Company or Uscom) today announced a material increase in USCOM 1A orders from China during the past five weeks, with some devices being specifically installed for the monitoring of hospital patients diagnosed with Coronavirus (2019-nCoV).
